Preclinical data from a study conducted by Enlivex Therapeutics in collaboration with Yale Cancer Center showed substantial and statistically significant improvements in survival benefit, survival duration, and tumor burden reduction in ovarian cancer when Allocetra was combined with an anti-PD1 checkpoint inhibitor.Â
Positive updated clinical research highlights the therapeutic potential of CLN-081 in patients with epidermal growth factor receptor exon 20 insertion mutation positive non-small cell lung cancer.Â
Data from pivotal trials of sugemalimab, a PD-L1 inhibitor, and aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor, demonstrated the potential clinical benefit of these investigational medicines in non-small cell lung cancer and of sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.
Several studies sponsored by Invitae underscore the importance of genetic testing for improving cancer outcomes, according to the company. These data will be presented at the 2022 ASCO annual meeting.
Several ongoing trials demonstrate that CPI-613 (devimistat) is a potential treatment for pancreatic cancer, clear cell sarcoma, and biliary tract cancer.Â
Updated data have emerged from the ELAINE-2 clinical trial of lasofoxifene plus abemaciclib in women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.Â
FDA approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy (ipilimumab) as first-line treatments for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, regardless of PD-L1 status.Â
FDA granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.Â
FDA approved for priority review the Biologics License Application for Omblastys (omburtamab) in the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.Â
FDA granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
